Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals

Argote, Mathilde; Sescousse, Guillaume; Brunelin, Jérôme; Baudin, Grégoire; Schaub, Michael Patrick; Rabin, Rachel; Schnell, Thomas; Ringen, Petter Andreas; Andreassen, Ole Andreas; Addington, Jean Margaret; Brambilla, Paolo; Delvecchio, Giuseppe; Bechdolf, Andreas; Wobrock, Thomas; Schneider-Axmann, Thomas; Herzig, Daniela; Mohr, Christine; Vila-Badia, Regina; Rodie, Judith Usall; Mallet, Jasmina; Ricci, Valerio; Martinotti, Giovanni; Knížková, Karolína; Rodriguez, Mabel; Cookey, Jacob; Tibbo, Philip; Scheffler, Freda; Asmal, Laila; Garcia-Rizo, Clemente; Amoretti, Silvia; Huber, Christian; Thibeau, Heather; Kline, Emily; Fakra, Eric; Jardri, Renaud; Nourredine, Mikail; Rolland, Benjamin

doi:10.1016/j.eclinm.2023.102199

Cited by 4 publications

(1 citation statement)

References 68 publications

(93 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most noticeable gender difference in the examination of the dual diagnosis referrals to DDCSCM is present with males living with schizophrenia and either co-occurring methamphetamine and cannabis use. The five-times higher rate of cannabis use for males with schizophrenia is consistent with other research in this area, which also reports a lifetime prevalence of co-occurring cannabis use and schizophrenia as high as 42% (Argote et al , 2023). Further understanding of the cannabis relationship in the context of gender and potential harms within a clinical mental health service context may also be fruitful in the development of more effective integrated treatment responses (Hjorthøj et al , 2023).…”

Section: Discussionsupporting

confidence: 89%

Connections between specific mental health diagnoses of schizophrenia, bipolar disorder and schizoaffective disorder and primary substance use

Foster,

Taylor,

Gough

2024

ADD

View full text Add to dashboard Cite

Purpose This study aims to use the database of consumers referred to the dual diagnosis shared care service to examine those connections. The Eastern Dual Diagnosis Service, based in Melbourne, Australia, has established a database of consumers with co-occurring mental health disorders and problematic substance use. An examination of mental health and substance-use information obtained over a two-year period in the delivery of dual diagnosis shared care to consumers of mental health services is supporting an improved understanding of substance use and the connections to specific mental health diagnoses of schizophrenia, bipolar disorder and schizoaffective disorder. Design/methodology/approach This research uses a quantitative approach to review the prevalence of primary substance use and mental health diagnoses for consumers referred to as dual diagnosis shared care. Reviewed are referrals from adult mental health community and rehabilitation teams operating within a mental health and well-being program between January 2019 and December 2020 inclusive. Findings Of the 387 clients referred to the specialist dual diagnosis shared care, methamphetamine, alcohol and cannabis are associated with 89.4% of the primary mental health diagnosis (PMHD). The most common PMHDs are schizophrenia, schizoaffective disorder and bipolar disorder. The most common PMHD and substance-use connection was schizophrenia and methamphetamine. Nicotine was reported to be used by 84% of consumers and often occurred in addition to another problematic primary substance. Originality/value Improved dual diagnosis data collection from a community-based clinical mental health service is increasing understanding of the mental health and substance-use relationship. This is now providing clarity on routes of investigation into co-occurring mental health and problematic substance-use trends and guiding improved integrated treatments within a contemporary mental health setting.

show abstract

Section: Discussionsupporting

confidence: 89%

Connections between specific mental health diagnoses of schizophrenia, bipolar disorder and schizoaffective disorder and primary substance use

Foster,

Taylor,

Gough

2024

ADD

View full text Add to dashboard Cite

show abstract

Complete blood count-based inflammation indexes and symptom severity in people with schizophrenia spectrum disorders: An analysis based on structural equation modelling

Cavaleri,

De Pietra,

Gazzola

et al. 2024

Psychoneuroendocrinology

View full text Add to dashboard Cite

Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia

Lesh,

Rhilinger,

Brower

et al. 2024

Schizophrenia Bulletin Open

View full text Add to dashboard Cite

While continued cannabis use and misuse in individuals with schizophrenia is associated with a variety of negative outcomes, individuals with a history of use tend to show higher cognitive performance compared to non-users. While this is replicated in the literature, few studies have used task-based functional magnetic resonance imaging (fMRI) to evaluate whether the brain networks underpinning these cognitive features are similarly impacted. Forty-eight first episode individuals with schizophrenia (FES) with a history of cannabis use (FES+CAN), 28 FES individuals with no history of cannabis use (FES-CAN), and 59 controls (CON) performed the AX-Continuous Performance Task during fMRI. FES+CAN showed higher cognitive control performance (d’-context) compared to FES-CAN (p<.05, ηp2=.053), and both FES+CAN (p<.05, ηp2=.049) and FES-CAN (p<.001, ηp2=.216) showed lower performance compared to CON. FES+CAN (p<.05, ηp2=.055) and CON (p<.05, ηp2=.058) showed higher dorsolateral prefrontal cortex (DLPFC) activation during the task compared to FES-CAN, while FES+CAN and CON were not significantly different. Within the FES+CAN group, younger age of initiation of cannabis use was associated with lower IQ and lower global functioning. More frequent use was also associated with higher reality distortion symptoms at the time of the scan. These data are consistent with previous literature suggesting that individuals with schizophrenia and a history of cannabis use have higher cognitive control performance. For the first time, we also reveal that FES+CAN have higher DLPFC brain activity during cognitive control compared to FES-CAN. Several possible explanations for these findings are discussed.

show abstract

Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals

Cited by 4 publications

References 68 publications

Connections between specific mental health diagnoses of schizophrenia, bipolar disorder and schizoaffective disorder and primary substance use

Connections between specific mental health diagnoses of schizophrenia, bipolar disorder and schizoaffective disorder and primary substance use

Complete blood count-based inflammation indexes and symptom severity in people with schizophrenia spectrum disorders: An analysis based on structural equation modelling

Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia

Contact Info

Product

Resources

About